Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramosetron vs Psyllium for Fecal Incontinence
NCT06166615Phase 3Active, not recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Jan 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ramosetron in fecal incontinence (FI) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Fecal Incontinence Severity Index at 1 month. Started Jan 2024; status: active, not recruiting.
02
Drugs
ramosetron
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on NCT06166615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06166615.